Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma. (Record no. 3802)

000 -LEADER
fixed length control field 02866nam a22004337a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 170428s20172017 xxu||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
Classification number 28114256
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1528-9117
190 ## -
-- Christiansen SA
190 ## -
-- Khan S
190 ## -
-- Gibney GT
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Khan, Shaheer
245 ## - TITLE STATEMENT
Title Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.
251 ## -
-- Cancer Journal. 23(1):59-62, 2017 Jan/Feb
252 ## -
-- Cancer J. 23(1):59-62, 2017 Jan/Feb
253 ## -
-- Cancer journal (Sudbury, Mass.)
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Date of publication, distribution, etc. 2017
269 ## -
-- FY2017
501 ## - WITH NOTE
With note Available online through MWHC library: 2002 - present
520 ## - SUMMARY, ETC.
Summary, etc. In recent years, the field of oncology has witnessed many breakthroughs in the treatment of advanced malignancies, particularly in patients with advanced melanoma. Targeted and immune checkpoint therapies have emerged as the primary treatment strategies for these patients. Molecular profiling of melanoma is incorporated into routine practice to identify potential therapeutic targets, and patients are offered either a targeted or immune checkpoint inhibitor therapy approach. Both strategies have limitations where not all patients experience durable responses. Preclinical data have demonstrated the ability of targeted therapy to enhance activity of effector T cells, reduce immunosuppressive cytokine production, and increase tumor cell antigen presentation, which can augment antitumor immunity. In vivo models have shown synergy with improved tumor control when targeted and immune checkpoint agents are combined. Therefore, combination strategies with targeted and immune checkpoint therapy may improve patient outcomes. Early clinical data with anti-programmed cell-death protein 1/programmed cell-death ligand 1 agents in combination with targeted inhibitors appear to have acceptable toxicity rates and the potential for enhanced antitumor activity. This review explores the current status of preclinical and clinical development for these combination approaches in patients with advanced melanoma.
546 ## - LANGUAGE NOTE
Language note English
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Geographic name MedStar Washington Hospital Center
656 ## - INDEX TERM--OCCUPATION
Occupation Medicine
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Combined Modality Therapy
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Endpoint Determination
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Immunotherapy/mt [Methods]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Melanoma/dt [Drug Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Melanoma/im [Immunology]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Melanoma/pa [Pathology]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Melanoma/th [Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Molecular Targeted Therapy
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Randomized Controlled Trials as Topic
657 ## - INDEX TERM--FUNCTION
Function Journal Article
857 ## -
-- https://dx.doi.org/10.1097/PPO.0000000000000245
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00130404-201701000-00009&LSLINK=80&D=ovft
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection code Permanent Location Current Location Date acquired Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 2017-05-06 28114256 2017-05-06 2017-05-06 Journal Article

Powered by Koha